Qiagen NV | QIA - 销售和管理费用

金融业

USD

USD 5.89B

现金及等价物

USD 646.29M

USD 196.45M

USD 1.66B

USD 581.45M

USD 1.65B

股息收益率

USD 0.9

USD 141.4M

USD 207.66M

USD 6.18K

EPS每股收益

USD 0.54

股本和储备

USD 3.36B

USD 340.39M

债务利息支出

USD 10.02M

USD 10.56M

USD 1.63B

USD 8.36B

USD 103.4M

USD 393.64M

USD 141.4M

普通股股本

USD 206.5M

16.72

USD 157.91M

USD 463.12M

销售和管理费用

USD 142.33M

USD 309.61M

贸易债权人

USD 79.08M

应收帐款人

USD 398.35M

	销售和管理费用	更改		日
Akebia Therapeutics	USD 23.53M		3.19M	2025-12
Alaunos Therapeutics	USD 447K		138K	2026-03
argenx SE	USD 417M		62M	2026-06
Avita Medical	AUD 19.03M		1.95M	2025-12
Dianthus Therapeutics	USD 12.47M		5.89M	2026-03
Ionis Pharmaceuticals	USD 130.07M		20.92M	2026-06
IQVIA Holdings	USD 574M		72M	2026-06
Moderna	USD 216M		43M	2026-06
Organon & Co	USD 434M		10M	2026-06
Qiagen NV	USD 142.33M		60K	2026-06
Revvity	USD 278.58M		24.69M	2026-06
Tectonic Therapeutic	USD 6.43M		2.99M	2026-03
Viatris	USD 1.13B		205.7M	2026-06
Xeris Pharmaceuticals	USD 53.14M		10.51M	2026-03